KMWM
KYMR icon

Keudell/Morrison Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$598K Sell
5,215
-1,775
-25% -$153K 0.11% 123
2026
Q1 		$582K Buy
6,990
+390
+6% +$30.9K 0.12% 116
2025
Q4 		$514K Buy
+6,600
New +$446K 0.11% 129
2025
Q2 		$334K Buy
+7,660
New +$264K 0.07% 158
2024
Q4 		– Sell
-4,830
Closed -$229K – 230
2024
Q3 		$229K Sell
4,830
-2,275
-32% -$100K 0.06% 192
2024
Q2 		$212K Buy
7,105
+480
+7% +$16.6K 0.06% 193
2024
Q1 		$266K Buy
+6,625
New +$237K 0.08% 169

Other funds holding KYMR

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Keudell/Morrison Wealth Management's KYMR Position: Q2 2026 in Review

Keudell/Morrison Wealth Management reduced its Kymera Therapeutics (KYMR) stake by 25% in Q2 2026, selling an estimated $153K and leaving 5,215 shares worth $598K. The position accounts for 0.11% of the portfolio, ranked #123.

Keudell/Morrison Wealth Management first reported a position in KYMR in Q1 2024 and has held it in 7 quarters since. 12 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Keudell/Morrison Wealth Management held 5,215 shares of Kymera Therapeutics worth $598K as of Q2 2026.
  • Keudell/Morrison Wealth Management sold 1,775 Kymera Therapeutics shares in Q2 2026, an estimated $153K.
  • Kymera Therapeutics made up 0.11% of Keudell/Morrison Wealth Management's portfolio in Q2 2026, its #123 holding.
  • Keudell/Morrison Wealth Management first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 12 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Keudell/Morrison Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.